An investigation for investors in Zymeworks Inc (NYSE:ZYME) shares over potential securities laws violations by Zymeworks Inc was announced.
San Diego, CA -- (SBWIRE) -- 12/19/2017 -- Zymeworks Inc is under investigation over potential securities laws violations in connection with certain financial statements. The investigation was announced for investors in NYSE:ZYME shares.
Investors who purchased shares of Zymeworks Inc (NYSE:ZYME) should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm focuses on whether a series of statements by Zymeworks Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. Zymeworks Inc reported that its annual Total Revenue rose from $9.66 million in 2015 to $11.01 million in 2016. On April 28, 2017, Zymeworks Inc sold 4.5 million shares of stock in its initial public stock offering (the "IPO"), raising $58.50 million in new capital. However, since the IPO, Zymeworks Inc stock declined to as low as $7.26 per share.
Those who purchased shares of Zymeworks Inc (NYSE:ZYME) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels